A detailed history of Janus Henderson Group PLC transactions in United Therapeutics Corp stock. As of the latest transaction made, Janus Henderson Group PLC holds 460,419 shares of UTHR stock, worth $167 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
460,419
Previous 410,010 12.29%
Holding current value
$167 Million
Previous $131 Million 26.33%
% of portfolio
0.09%
Previous 0.07%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$311.04 - $363.55 $15.7 Million - $18.3 Million
50,409 Added 12.29%
460,419 $165 Million
Q2 2024

Aug 14, 2024

SELL
$228.26 - $319.04 $51.4 Million - $71.9 Million
-225,337 Reduced 35.47%
410,010 $131 Million
Q1 2024

May 15, 2024

SELL
$210.76 - $249.51 $49.5 Million - $58.6 Million
-234,772 Reduced 26.98%
635,347 $146 Million
Q4 2023

Feb 14, 2024

SELL
$214.88 - $256.94 $1.39 Million - $1.66 Million
-6,449 Reduced 0.74%
870,119 $191 Million
Q3 2023

Nov 14, 2023

SELL
$211.82 - $248.24 $482,102 - $564,994
-2,276 Reduced 0.26%
876,568 $198 Million
Q2 2023

Aug 14, 2023

SELL
$205.19 - $232.99 $19.9 Million - $22.6 Million
-96,986 Reduced 9.94%
878,844 $194 Million
Q1 2023

May 15, 2023

BUY
$212.99 - $276.17 $44.4 Million - $57.6 Million
208,404 Added 27.16%
975,830 $219 Million
Q4 2022

Feb 14, 2023

SELL
$205.95 - $280.43 $11.8 Million - $16.1 Million
-57,395 Reduced 6.96%
767,426 $213 Million
Q3 2022

Nov 14, 2022

BUY
$203.3 - $244.17 $23.8 Million - $28.6 Million
117,016 Added 16.53%
824,821 $173 Million
Q2 2022

Aug 15, 2022

BUY
$174.81 - $241.14 $16.6 Million - $22.9 Million
94,843 Added 15.47%
707,805 $167 Million
Q1 2022

May 16, 2022

BUY
$166.16 - $213.96 $90.5 Million - $117 Million
544,649 Added 797.28%
612,962 $110 Million
Q4 2021

Feb 14, 2022

BUY
$184.32 - $216.08 $11.2 Million - $13.1 Million
60,658 Added 792.4%
68,313 $14.8 Million
Q3 2021

Nov 16, 2021

BUY
$179.86 - $214.88 $1.38 Million - $1.64 Million
7,655 New
7,655 $1.41 Million
Q2 2021

Aug 16, 2021

SELL
$170.47 - $211.93 $2.16 Million - $2.69 Million
-12,691 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$153.94 - $174.85 $935,031 - $1.06 Million
-6,074 Reduced 32.37%
12,691 $2.12 Million
Q4 2020

Feb 16, 2021

SELL
$101.87 - $151.79 $844,196 - $1.26 Million
-8,287 Reduced 30.63%
18,765 $2.85 Million
Q3 2020

Nov 16, 2020

BUY
$99.9 - $121.13 $1.18 Million - $1.43 Million
11,809 Added 77.47%
27,052 $2.73 Million
Q2 2020

Aug 14, 2020

BUY
$92.74 - $125.82 $725,041 - $983,660
7,818 Added 105.29%
15,243 $1.84 Million
Q1 2020

May 14, 2020

SELL
$79.39 - $115.35 $3,810 - $5,536
-48 Reduced 0.64%
7,425 $704,000
Q4 2019

Feb 18, 2020

BUY
$78.31 - $95.34 $195,853 - $238,445
2,501 Added 50.3%
7,473 $658,000
Q3 2019

Nov 14, 2019

BUY
$74.85 - $85.99 $62,125 - $71,371
830 Added 20.04%
4,972 $396,000
Q2 2019

Jul 31, 2019

SELL
$76.06 - $120.81 $724,927 - $1.15 Million
-9,531 Reduced 69.71%
4,142 $323,000
Q1 2019

Apr 30, 2019

SELL
$107.15 - $126.84 $661,329 - $782,856
-6,172 Reduced 31.1%
13,673 $1.61 Million
Q4 2018

Feb 06, 2019

BUY
$101.4 - $128.73 $713,146 - $905,358
7,033 Added 54.89%
19,845 $2.16 Million
Q3 2018

Nov 09, 2018

SELL
$113.81 - $129.46 $488,586 - $555,771
-4,293 Reduced 25.1%
12,812 $1.64 Million
Q2 2018

Aug 10, 2018

SELL
$101.14 - $118.31 $2.55 Million - $2.98 Million
-25,206 Reduced 59.57%
17,105 $1.94 Million
Q1 2018

May 14, 2018

BUY
$107.21 - $151.94 $502,278 - $711,838
4,685 Added 12.45%
42,311 $4.75 Million
Q4 2017

Feb 09, 2018

SELL
$118.58 - $151.28 $1.06 Million - $1.35 Million
-8,920 Reduced 19.16%
37,626 $5.57 Million
Q3 2017

Nov 14, 2017

SELL
$114.6 - $136.81 $2.69 Million - $3.21 Million
-23,478 Reduced 33.53%
46,546 $0
Q2 2017

Aug 17, 2017

BUY
N/A
70,024
70,024 $9.08 Million

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.6B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.